NanoSomiX

Unlocking the Mysteries of the Brain

The brain is the most complex and least understood organ in the body. NanoSomiX, Inc. is at the forefront in establishing an entirely new class of non-invasive testing to address the need for improved brain analytic tools for research and clinical applications using Brain Derived Exosomes (BDE). We are interested in working collaboratively with researchers worldwide to use our blood-based assay technology to further biomarker exploration in neurodegenerative diseases.

Exosomes are extremely small, membrane-bound vesicles produced by cells throughout the body. NanoSomiXis specifically focused on BDEs – exosomes produced by various brain cell populations. A characteristic of BDEs is that they carry brain-produced biomarkers that relate to brain function. With a simple blood draw, pathologic forms or modulation of certain biomarkers can be assessed by our technology. This biomarker assessment can provide needed information about the health and current status of the different brain cell types.

Our laboratory is working with both academic researchers and commercial companies to support ongoing research into biomarkers associated with various neurologic diseases and neurotrauma. Much of our contract work involves studies to confirm the detection of specific biomarkers of interest, and to design protocols for diagnostic or monitoring applications. Working within a CLIA laboratory environment, we can provide a blood-based assay that is repeatable, cost effective and fits easily into a routine diagnostic or research environment.

Our proprietary exosome isolation technology is covered by a recently granted patent, with 5 additional patent applications in process to cover various aspects of BDE processing and marker application. Using BDEs to explore clinical applications in neurodegenerative diseases is supported by several peer-reviewed publications. We are ready to work with you to help move your important biomarker projects forward.


News and Events

5/18/18 - NanoSomiX, Inc. Announces Issuance of First US Patent

NanoSomiX, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the company’s first patent covering its groundbreaking proprietary exosome isolation and biomarker detection technology.

Read More

4/12/18 - Published study shows biomarker promise for neurotrauma recovery monitoring

NanoSomiX has further expanded its diagnostic applications which utilize its patented Brain Derived Exosome technology. A recently published study in Frontiers in Neurology tested a unique panel of blood biomarkers using this enhanced approach to evaluate the recovery process after sport-related neurotrauma.

Read More

In The News